Quantcast

CutisPharma, Inc. is on the Move

May 21, 2014

CutisPharma has moved to a larger facility to support growth

WILMINGTON, Mass., May 21, 2014 /PRNewswire/ — CutisPharma, Inc. announced its move to a new location at 841 Woburn St. Wilmington, MA. “We are pleased to announce our relocation to a larger facility to support our record growth,” said Dr. Indu Muni, founder, chairman, and CEO of CutisPharma, Inc. “The move will help to maintain our expansion, particularly in the areas of Research and Development, Customer Service, and Operations.”

“Our Company Mission Statement is to simplify the practice of traditional pharmacy compounding and to improve end user’s (Customers’) satisfaction for compounded drug products,” said Dr. Indu Muni.

CutisPharma now has twenty four proprietary prescription compounding kits on the market: five progesterone suppository compounding kits, two testosterone kits, one hydrocortisone kit, five Magic Mouthwash kits, three omeprazole suspension kits, three lansoprazole suspension kits, and five vancomycin solution kits. Several more compounding kits are in the planning stages. The use of FIRST® Unit-of-Use Prescription Compounding Kits facilitates compliance with United States Pharmacopeia (USP) Chapter <795>.

The prescription compounding business is estimated to be worth as much as $9 billion annually, according to Pharmacy Commerce May/June 2013 issue. Prescriptions are prepared through “compounding,” a means by which a pharmacist prepares a customized medication according to a doctor’s prescription to meet an individual patient’s medical need.

About CutisPharma
CutisPharma, Inc. based in Wilmington, MA, is a privately held, specialty pharmaceutical company focusing on the development and commercialization of value-added proprietary drug products and technologies in the prescription compounding sector of the pharmaceutical industry. Product line and development efforts are focused on providing optimized, more efficient alternatives for the preparation of the nearly 20 million currently compounded prescriptions, by offering FIRST(®) Unit-of-Use Prescription Compounding Kits. Use of these branded compounding kits will be beneficial to all triad participants, namely physicians, pharmacists, and patients. Four U.S. patents have been issued to the Company with additional patents pending, including “Composition and Method for Vancomycin Oral Liquid”.

For more information please visit our website at www.cutispharma.com

SOURCE CutisPharma, Inc.


Source: PR Newswire



comments powered by Disqus